Aileron Therapeutics Announces Positive Nonclinical Myelopreservation Results for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference

Aileron to Present Nonclinical Myelopreservation Data for ALRN-6924 at the 2019 AACR-NCI-EORTC Conference on October 29th

Aileron Therapeutics Announces the Initiation of Patient Treatment in its First Clinical Ph1b/2 Trial of ALRN-6924 as a Myelopreservation Agent

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Aileron to Present Interim Phase 2a Clinical Data for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers at the 2019 Congress of the European Society for Medical Oncology

Aileron Therapeutics Announces Management Change

Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

Aileron Therapeutics Reports Second Quarter 2019 Financial Results

Aileron Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference

Aileron Therapeutics to Report Second Quarter 2019 Financial Results on August 6, 2019